News & Events

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 18, 2026, Palatin Technologies, Inc. (the “Company”), acting pursuant to authorization from its Board of Directors, provided notice to the NYSE American LLC (the “NYSE”) that it intends to voluntarily withdraw the listing of its common stock, par value $0.01 per share (the “common stock”), from the NYSE and transfer the listing of its common stock to the Nasdaq Capital Market (the “Nasd…

Entry into a Material Agreement. On November 5, 2025, Palatin Technologies, Inc. entered into an underwriting agreement with A.G.P./Alliance Global Partners (the “ Underwriting Agreement ”) relating to the Company’s public offering of 2,430,769 shares of common stock (or pre-funded warrants in lieu thereof) together with Series J warrants to purchase up to 2,430,769 shares of common stock (the “ Series J Warrants ”), and Series K warrants to purchase up to 2,430,769 shares of common stock (th…

Other Events. NYSE American Listing Compliance On August 11, 2025, a reverse stock split of the Company’s outstanding shares of common stock took effect at a ratio of one-for-fifty (the “ Reverse Stock Split ”). The Reverse Stock Split resulted in the Company becoming compliant with Section 1003(f)(v) of the NYSE American Company Guide. On November 5, 2025, the Company submitted to NYSE American, on a pro-forma basis, as of November 5, 2025, financial statements demonstrating its compliance w…

Other Events. On September 22, 2025, Palatin issued a press release announcing the achievement of a research milestone under its collaboration with Boehringer Ingelheim. This milestone triggers a €5.5 million ($6.5 million) payment to Palatin.. The press release is furnished as Exhibit 99.1 and incorporated by reference herein. Under the terms of the agreement, Palatin received an upfront payment of €2.0 million ($2.3 million USD) and is eligible for up to €18.0 million ($21.2 million USD) in…

Entry into a Material Definitive Agreement. On August 14, 2025, Palatin Technologies Inc. (“Palatin”), entered into a Research Collaboration, License and Patent Assignment Agreement (the “Agreement”) with Boehringer Ingelheim International GmbH (“BI”) to research, develop and commercialize first-in-class melanocortin receptor-targeted peptides developed by Palatin for the treatment of retinal diseases, including diabetic retinopathy. Under the terms of the Agreement, Palatin assigned certain…

Regulation FD Disclosure. On August 18, 2025, BI and Palatin issued a press release announcing entering into the Agreement. The press release is furnished as Exhibit 99.1 and incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such…

Regulation FD Disclosure. The Reverse Stock Split is expected to become effective after market on August 11, 2025 with the Company’s Common Stock to begin trading on the OCTQB Market of the OTC Markets Group on a split-adjusted basis at market open on August 12, 2025. The revised timing of the Reverse Stock Split is due to delayed approval from the Financial Industry Regulatory Authority, which we expect after market on August 11, 2025. Forward-Looking Statements This Current Report includes…

Regulation FD Disclosure. On August 8, 2025, the Company issued a press release announcing the Reverse Stock Split. The press release is furnished as Exhibit 99.1 and incorporated by reference herein. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such informat…

Material Modification to Rights of Security Holders. To the extent required by

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 7, 2025, Palatin Technologies, Inc. (the “Company”) received written notification from NYSE American LLC (“NYSE American” or the “Exchange”) stating that a Listing Qualifications Panel (the “Panel”) of the Exchange’s Committee for Review (the “Committee for Review”) had unanimously determined to affirm the decision of the staff of NYSE American to initiate delisting proceedings of the…

The Preferred Stock, Warrants, Conversion Shares, and Warrant Shares described in this Current Report on Form 8-K have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and were offered and sold in reliance upon an exemption from the registration requirements under Section 4(a)(2) under the Securities Act and/or Regulation D promulgated thereunder.

Entry into a Material Definitive Agreement. On June 10, 2025, Palatin Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue, in a private placement (the “Private Placement”), (i) an aggregate of 3,400 shares of the Company’s newly designated Series D Convertible Preferred Stock, par value $0.01, with a stated value of $100 per share…

Entry into a Material Definitive Agreement. On May 7, 2025, Palatin Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors named on the signature pages thereto pursuant to which the Company agreed to sell and issue, in a reasonable best efforts registered public offering (the “Offering”), an aggregate of 76,666,667 shares of common stock, $0.01 par value per share, of the Company (the “Shares”) of which also cons…

below. A copy of such press release is attached as Exhibit 99.1 and is incorporated herein by reference. Also on May 7, 2025, certain investors notified the Company that an event listed under Section 2.3(b)(v) of the Purchase Agreement had occurred and that such investors would not proceed to closing in connection with the Offering. As a result, on May 8, 2025, the Company raised approximately $1.1 million in net proceeds from the reduced Offering. The Company intends to use the net proceeds…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On April 10, 2025, Palatin Technologies, Inc. (the “Company”) received written notification from NYSE American LLC (“NYSE American” or the “Exchange”) stating that the NYSE Regulation has determined to commence proceedings to delist the Company’s common stock, par value $0.01 per share (the “Common Stock”) from NYSE American. NYSE Regulation has determined that the Company is no longer suitabl…

Forward-Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and involve certain risks and uncertainties, including the trading in the Company’s Common Stock on the NYSE American and the Company’s ability to appeal the delisting of the Common Stock by NYSE American. Additional information and key risks applic…

Entry into a Material Definitive Agreement. On February 11, 2025, Palatin Technologies, Inc. (the “Company”) entered into an At the Market Issuance Sales Agreement (the “Sales Agreement”), with A.G.P./Alliance Global Partners (“A.G.P.”), pursuant to which the Company may, from time to time, offer and sell, through A.G.P., as a sales agent or principal, shares of the Company’s common stock, par value $0.01 per share (the “Shares”), having an aggregate offering price of up to approximately $6.0…

Entry into a Material Definitive Agreement. On February 6, 2025, Palatin Technologies, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor, to sell in a registered direct offering (the “RD Offering”), an aggregate of 2,550,000 shares of common stock, $0.01 par value per share (the “Shares”), of the Company and pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 2,138,000 shares of common stock of the Company…

The Private Warrants and the Private Warrant Shares described in this Current Report on Form 8-K have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and were offered and sold in reliance upon an exemption from the registration requirements under Section 4(a)(2) under the Securities Act and/or Regulation D promulgated thereunder.